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Abstract
The heterogeneous and chaotic nature of osteosarcoma has confounded accurate molecular
classification, prognosis, and prediction for this tumor. The occurrence of spontaneous
osteosarcoma is largely confined to humans and dogs. While the clinical features are remarkably
similar in both species, the organization of dogs into defined breeds provides a more homogeneous
genetic background that may increase the likelihood to uncover molecular subtypes for this
complex disease. We thus hypothesized that molecular profiles derived from canine osteosarcoma
would aid in molecular subclassification of this disease when applied to humans. To test the
hypothesis, we performed genome wide gene expression profiling in a cohort of dogs with
osteosarcoma, primarily from high-risk breeds. To further reduce inter-sample heterogeneity, we
assessed tumor-intrinsic properties through use of an extensive panel of osteosarcoma-derived cell
lines. We observed strong differential gene expression that segregated samples into two groups
with differential survival probabilities. Groupings were characterized by the inversely correlated
expression of genes associated with G2/M transition and DNA damage checkpoint and
microenvironment-interaction categories. This signature was preserved in data from whole tumor
samples of three independent dog osteosarcoma cohorts, with stratification into the two expected
groups. Significantly, this restricted signature partially overlapped a previously defined, predictive
signature for soft tissue sarcomas, and it unmasked orthologous molecular subtypes and their
corresponding natural histories in five independent data sets from human patients with
osteosarcoma. Our results indicate that the narrower genetic diversity of dogs can be utilized to
group complex human osteosarcoma into biologically and clinically relevant molecular subtypes.
This in turn may enhance prognosis and prediction, and identify relevant therapeutic targets.
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1. Introduction
Etiological similarities have been observed between human and canine tumors for a number
of cancers [1]. Indeed, we have shown that orthologous molecular abnormalities drive
homologous, cytogenetically stable tumors such as chronic myelogenous leukemia [2] in
both species, but whether the evolutionary conservation of driver abnormalities also can be
identified in cytogenetically chaotic tumors such as osteosarcoma remains an open question.
Discreet and reproducible molecular subtypes have been described previously for various
human tumors such as diffuse large B-cell lymphoma [3] and breast cancer [4]; however,
multiple studies using genome-wide approaches have failed to show consistent, orthologous
signatures that define molecularly distinct subtypes of osteosarcoma [5–11]. Nonetheless,
recent studies identified (1) a minimal common predictive gene signature in human soft
tissue sarcomas [12], (2) predictable commonalities between humans and dogs when gene
expression profiles from normal liver, kidney, and lymph node were compared to those from
osteosarcoma [13], and (3) differential gene expression among dog tumors with differential
times to metastasis [14]. Here, we conducted gene expression analysis using a subset of
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canine osteosarcoma samples, applying diverse strategies to further reduce complexity and
genetic heterogeneity, and then used these data to identify functionally and biologically
significant subtypes of human osteosarcoma.
2. Materials and Methods
2.1 Canine sample accrual
Samples were obtained from dogs with naturally occurring primary appendicular
osteosarcoma recruited over a time period of 10 years (1999–2009). Tumor samples
represented every geographical region in the United States, with a recruitment strategy
designed around two breeds (Rottweilers and Golden Retrievers), but including samples
from other high-risk breeds. Specimens were obtained as part of medically necessary clinical
procedures prior to initiation of therapy with owner consent and under protocols approved
by the University of Minnesota Institutional Animal Care and Use Committee and the
Colorado Multiple Institutional Review Board. All samples were obtained prior to any
treatment with cytotoxic chemotherapy drugs (naïve disease). For five dogs, metastatic lung
tumor samples were obtained at necropsy. A summary of demographics and tumor
morphology for the 79 dogs recruited in this time period, and indicating the 27 samples used
for microarray analyses, are shown in Supplementary Table 1.
2.2 Derivation and maintenance of cultured cells, and cytotoxicity assays
Processing of tumor specimens and culture of cells derived from these tumors has been
described [15, 16]. All cell lines were derived in the Modiano lab from primary specimens
with a verified histopathologic diagnosis. The ontogeny of the cell lines was authenticated
by immunostaining for expression of alkaline phosphatase and osteocalcin. Canine origin
was confirmed cytogenetically using metaphase and array-based comparative genomic
hybridization and fluorescence in situ hybridization with canine specific probes in the Breen
lab. Half maximal inhibitory concentrations for paclitaxel were determined using the MTT
assay in cells cultured for 72 hr in the presence or absence of the drug [17].
2.3 RNA isolation and array hybridization
RNA was isolated from cryopreserved cells and tissue samples, quantified, and assessed for
quality as described previously [18]. The twenty-seven cell lines and six primary tumors
used were all suitable for microarray analysis based on cell viability and RNA quality (RIN
>6.5). Samples were hybridized to Affymetrix Canine_2.0 gene chips as described [18].
Two samples (OSCA-25 and OSCA-71) were done in duplicate, prepared by different
operators at different times and run on different microarray batches to control for intrinsic
variance in cell lines, for variance in operator technique, and for batch effects. The
correlation coefficient (r2) for expression values between duplicate samples was >0.95 in
both cases. To minimize redundancy, the values shown for these two samples are averages
from the two microarrays for each.
2.4 Data Analysis
Following hybridization, each chip passed quality assurance and control procedures using
Affymetrix quality control algorithms provided in Expressionist Refiner module (Genedata,
Basel, Switzerland, v. 5.2 and 5.3). Probe signal levels were quantile-normalized and
summarized using the GeneChip - Robust Multichip Averaging algorithm [19]. Resulting
normalized files were imported into Expressionist Analyst module (v. 5.3). Affymetrix
probe IDs were mapped to corresponding canine Entrez Gene IDs using Affymetrix NetAffx
EntrezGene Annotation. Canine Entrez Gene IDs were mapped to 17,482 gene names using
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data obtained from Entrez Gene FTP server update Dec 21, 2009. Canine gene names were
mapped to their associated human gene names by direct name matching.
Prior to unsupervised hierarchical clustering, normalized chip data were median-centered
and log2-transformed. Clustering was done using Gene Cluster 3.0 for Mac OS X (C
Clustering Library 1.47) correlation based on average linkage. Gene Cluster 3.0 data were
visualized in Java TreeView version 1.1.3. Two group T-tests were done to determine genes
that were differentially expressed between the two groups. Multiple testing correction was
done using the Benjamini-Hochberg (BH) correction. Genes with a p-value <0.0068 (BH p-
value ≤0.05) and average fold-change >3 were identified for further analysis. Gene
expression data were deposited in GEO (accession # GSE27217).
2.5 Canine osteosarcoma data
Two additional sets of data files with 15 canine osteosarcoma samples each were imported
from GEO into Expressionist Analyst module for analysis. One set (GSE16088) was
profiled on the Affymetrix Canine_1.0 platform [13], and the other (GSE24251) on the
Affymetrix Canine_2.0 platform [14].
2.6 Human osteosarcoma data
Five sets of data files from human osteosarcoma were imported into Expressionist Analyst
module for analysis. A set of 31 samples [8] was retrieved from the Translational Genomics
Research Institute website (http://tgen.org/research/index.cfm?pageid=663). The second set
of 20 samples of normal bone and osteosarcoma profiled on the Illumina bead array was
from patient samples originating at the University of Minnesota. The third set of 24
osteosarcoma samples was from Cleton-Jansen et al [9], available at
http://www.nature.com/bjc/journal/v101/n11/suppinfo/6605405s1.html?url=/bjc/journal/
v101/n11/full/6605405a.html. The fourth set of 27 osteosarcoma samples [11] and the fifth
set of 34 samples [13] were obtained from GEO (GSE14827 and GSE16091, respectively).
For all five independent sets, significantly differentially expressed canine genes were
mapped to human genes by name. All corresponding human genes were used for
unsupervised clustering of experiments as described above.
2.7 Network identification and canonical pathway analysis of differently expressed genes
Ingenuity Pathway Analysis (IPA) software v8.6 (Ingenuity Systems, Redwood City, CA)
was used to define functions and canonical pathways specifically enriched in the sets of
genes using BH multiple testing corrections to assess significance.
2.8 Real-time quantitative reverse transcriptase PCR
Elimination of genomic DNA and reverse transcription were both carried out using
QuantiTect Reverse Transcription Kit (Qiagen, Valencia, CA). Real-time quantitative
reverse transcriptase PCR (qRT-PCR) was performed on an Eppendorf Mastercycler ep
realplex with FastStart SYBR Green Master Mix Protocol (Roche, Indianapolis, IN). Primer
sequences are provided in Supplementary Table 2. GAPDH was used as the reference
standard for normalization and relative levels of steady state mRNA were established using
the comparative [delta][delta]Ct method [20]. The transcript levels in cells from the
osteomyelitis sample (OSCA-41) were adjusted to 1 and served as the reference. The
relationship between array and qRT-PCR values for the three transcripts of interest were
analyzed using Pearson s correlation.
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Decalcified, fixed and paraffin embedded tissues from which cell lines were derived were
used to stain sections as described (IHC Services, Smithville, TX) [21]. Cyclin B2
expression was detected using antibody sc-22776 (H-105) (Santa Cruz Biotechnology, Santa
Cruz, CA).
2.10 Statistics
Descriptive statistics for variables of breed, gender, age at diagnosis, histological subtype
and treatment regimen were performed. Categorical data are expressed as percentages, while
continuous data are expressed as medians (ranges). Fisher s exact test was performed to
compare data from the two sample subgroups (Branch A and Branch B). Overall survival
times were known for 21 of 26 osteosarcoma dogs included in the gene expression profiling
analysis. Five dogs were lost to follow up and the dog identified as OSCA 41 was
successfully treated for osteomyelitis. Survival time was defined as the interval from
diagnosis until death. All deaths were disease-related and none of the dogs had secondary
rescue after the diagnosis of metastatic disease. Kaplan-Meier analysis was done using
Prism5 from GraphPad software Inc. (San Diego, CA). Statistical significance was
calculated using the log rank test and a p< 0.05 was considered significant.
3. Results
3.1 Gene expression profiling segregates canine osteosarcoma into two distinct molecular
groups
Osteosarcoma is a morphologically and clinically heterogeneous disease. Specifically, the
molecular events responsible for the onset and progression of osteosarcoma are incompletely
understood. Osteosarcoma occurs naturally in dogs, with a strong breed preference,
providing opportunities to assess the role of heritable factors in causation and tumor
behavior [22]. To take advantage of this opportunity, we prospectively recruited a cohort of
79 dogs and used a subset of 27 representative samples, including 26 osteosarcomas and one
sample from a dog with osteomyelitis (Table 1) to generate genome-wide gene expression
profiles using the Affymetrix Canine 2.0 platform.
We focused our attention on tumor cell-autonomous gene signatures by using low-passage
cell lines, effectively reducing the intrinsic sample heterogeneity by filtering out the stromal
contributions [23]. Past studies of genome wide profiling in osteosarcoma have primarily
used supervised analyses according to pre-set criteria (“normal” vs. tumor, chemosensitivity
or percent necrosis, patient survival, anatomic location, primary vs. metastatic site, etc.).
Here, we used an unbiased approach to analyze genome wide gene expression data and
reveal biologically distinct sub-types of osteosarcoma. Specifically, we did not pre-assign
samples into groups, but instead allowed samples to cluster according to the degree with
which they shared similar gene expression profiles. Tumor cell line samples segregated into
two distinct branches (Figure 1A), Branch A (N=16 osteosarcoma) and Branch B (N=10
osteosarcoma and the osteomyelitis sample). Statistical analyses between these two groups
identified 282 genes with a BH p value ≤0.05 and showing a 200% (3-fold) average change
that were responsible for the clustering (Supplementary Table 3). Two reciprocally
expressed gene clusters were observed, represented as “Gene Cluster 1” and “Gene Cluster
2” in a standard heat map (Figure 1B).
The segregation of samples into distinct groups was robust. Whether we used the most
variable genes or included all genes profiled, we observed the same grouping of the samples,
suggesting that only a few biological processes drove this separation of osteosarcoma into
subgroups. Ingenuity Pathways analysis (IPA) was used to systematically identify functional
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processes associated with the 282 genes. The top functional annotations, corrected by BH
multiple testing, indicate that these genes as a group are strongly associated with cancer
related pathways (Table 2).
To further validate the array data, we selected a gene that showed significantly different
expression, with ~13-fold higher expression in Branch A (CCNB2), another with ~3-fold
higher expression in Branch A (CHEK2), and a third where the difference in expression
between Branch A and Branch B was <3-fold (CAD6), and assessed the levels for each in
nine samples run on the array using qRT-PCR. We then plotted the normalized array signal
(relative to GAPDH) for each gene as a function of its relative qRT-PCR-based mRNA level
(relative to GAPDH). Correlation values (R2) for these three genes were, respectively, 0.86,
0.72, and 0.83 (Figure 2). We then established the relevance of gene expression to intact
tumors using immunohistochemical staining for Cyclin B, using expression of the
intermediate filament Vimentin as a control, in three representative primary tumors selected
for “high”, “intermediate”, and “low” expression, and in the sample from the dog with
osteomyelitis (Figure 3). The data show that, while Vimentin expression in osteoblasts and
osteocytes was similar among all the samples, expression of Cyclin B2 protein was
consistent with the levels predicted from the arrays and the qRT-PCR experiment.
3.2 Cell cycle and microenvironment interaction gene clusters drive molecular and
pathologic stratification of canine osteosarcoma samples
We applied Ingenuity Pathway Analysis (IPA) to identify molecular pathways defined by
Gene Cluster 1 and Gene Cluster 2. Cluster 1 genes (n=125), which were over-expressed in
samples from Branch A dogs, were significantly enriched for genes involved in mitosis,
chromosome segregation, and mitotic spindle formation (Supplementary Figure 1A). Cluster
2 genes (n=157), which were over-expressed in samples from Branch B dogs, were
annotated to functions associated with the interactions that occur between cancer cells and
their microenvironment, such as cell migration, adhesion, angiogenesis, proliferation,
inflammation, and cell death (Supplementary Figure 1B).
3.3 Differential gene expression signatures are preserved in intact canine osteosarcoma
We next sought to determine if the cancer cell-autonomous gene expression signatures we
identified in our panel of canine osteosarcoma cell lines were present in intact tumor tissues.
We profiled six primary canine tumor tissues on Affymetrix Canine_2 gene chips and used
the 282-gene set described above to perform unsupervised hierarchical clustering of cell
lines and tumor tissues together. The branches and the reciprocal gene clusters were
preserved in this analysis with primary tumor samples segregating into both branches
(Figure 4A).
To track the pattern of expression observed in our samples in other, diverse sample sets, we
used a “gene vector-based” bioinformatic analytical strategy. We assigned a yellow or blue
tag to each gene vector in Cluster 1 and Cluster 2, respectively, where the color intensity
reflected the relative variation in expression observed in our samples. This methodology
allows direct comparative visualization of our vector patterns in independently derived
sample sets. We hypothesized that if the gene signature was relevant, the expression pattern
would be clearly observable in additional datasets where the blue and yellow tags would
cluster together independent of our results, thus confirming our observations.
As a first proof of this principle we obtained canine osteosarcoma gene expression profiles
generated in two previous studies from dogs with osteosarcoma diagnosed and treated at
Colorado State University, which were analyzed using both first- and second-generation
Affymetrix arrays [13, 14]. The first-generation arrays were incompletely annotated, so we
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were only able to map 31 genes; however, the patterns observed in our data were clearly
visible in this additional canine osteosarcoma tumor dataset, and the vector tags clustered
together (Figure 4B). Utilizing the additional OS samples derived from the Canine2.0
platform, the full 282-gene signature created two branches with >90% preservation of the
vector clustering and intensity on the Y-axis (Figure 4C) indicating that our results also were
observable in independent canine datasets.
3.4 The restricted gene expression signature generated from analysis of canine
osteosarcoma highlights molecularly homologous groups in independent cohorts of
humans with osteosarcoma
To determine if the molecular subtypes found in canine osteosarcoma also were present and
relevant to human osteosarcoma, we accessed published gene expression data from five
independent cohorts of human osteosarcoma and name mapped the 282-gene vectors to their
human homologues. These cohorts were geographically and ethnically diverse [9, 11, 13,
24], and each used a distinct platform for analysis. Unsupervised hierarchical clustering for
each of the human cohorts was consistent with the prediction of molecular homology,
resulting in similar clustering patterns for osteosarcoma samples to that observed in our dog
cohort (Figure 5). Approximately 50% of the gene vectors (140) were always present in each
group, and as we saw for the canine tumor samples, >90% remained in their respective
clusters showing comparable changes in the intensity of expression for the two major sample
branches (see blue and yellow tags for each gene vector in Figure 5).
The subset of canine cell lines and tissues from Figure 4 is reproduced in Figure 5A. Patient
samples in Figure 5B from a cohort of osteosarcoma patients from New York, USA [8]
showed clear separation into two branches with similar profiles to that seen in our canine
cohort. Figure 5C included two samples of normal bone (in duplicate), fifteen primary tumor
samples from Minnesota, USA, and three immortalized human osteosarcoma cell lines (in
duplicate). Notably, the normal bone samples in Figure 5C did not simply cluster together
alone, but instead they were part of a subgroup that included six osteosarcoma samples.
These samples had a gene expression signature that resembled canine Branch B, which itself
included the osteomyelitis (non-malignant) sample. The observation that non-malignant
samples clustered together with a subset of osteosarcomas in both dogs and humans
indicates that the gene expression signature associated with Branch B was not exclusively a
“normal bone” signature. Instead, this suggests that even after transformation, certain
osteosarcomas retain characteristics that resemble normal bone. This is consistent with the
degree of differentiation and pathological stratification that are defined for other tumors
such as breast cancer and myeloid leukemia, for example, but that had not previously been
achieved for bone cancer. Conversely, the immortalized cell lines in Figure 5C clustered
together and showed a gene expression signature similar to canine Branch A samples,
suggesting the cell lines originated from - or after selection in culture acquired features of -
tumors that retained fewer characteristics associated with normal bone cells. Figure 5D
illustrates samples from a European cohort of osteosarcoma patients [9] that was previously
shown to show enrichment of genes associated with cell cycle regulation and DNA
replication in osteosarcoma samples [9]. Whereas unsupervised analysis by Cleton-Jansen et
al was unsuccessful to define molecular subgroups in this cohort, application of our
restricted signature allowed for robust, unbiased separation of this cohort without into two
defined subgroups driven by patterns of gene expression. Figure 5E shows data from 27
tumor samples from Japanese osteosarcoma patients [11]. Here again, the use of our
restricted signature unmasked two distinct subgroups in this cohort that were not evident
from the original analysis. Figure 5F shows data from 34 samples from the National
Institutes of Health (Maryland, USA), reported by Paoloni et al [13]. In this case, our
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signature once again generated two subgroups defined by expression of the two conserved
and inversely related gene clusters.
3.5 Molecular subgroups of canine osteosarcoma predict biological behavior
To establish the potential clinical and biological relevance of the molecular grouping we
identified in the canine samples (section 3.1), we evaluated associations between the two
branches and population demographics, histopathological classifications, and overall
survival (Table 3). Among the variables examined, overall survival was statistically
significantly different (p<0.03), and breed showed a modest trend (p = 0.12 for Rottweilers
vs. non-Rottweilers), between Branch A and Branch B (Table 3). The significant difference
in overall survival between the 21 dogs with osteosarcoma and follow-up information in
Branch A and Branch B also was evident using Kaplan-Meier probability analysis and the
log rank test (p<0.01, Figure 6), with Branch A showing worse outcome than Branch B. Not
surprisingly, the osteomyelitis sample clustered with Branch B samples, suggesting that
tumor cells from dogs with longer overall survival were more similar to non-malignant,
reactive osteoblasts than to tumor cells from dogs with shorter overall survival. This
difference remained (p=0.01) when we included only the 15 dogs treated with standard of
care (amputation of the affected limb and adjuvant chemotherapy using doxorubicin or
carboplatin), indicating the separation into two branches was driven by tumor behavior, and
in this analysis, segregation into Branch A or Branch was independent of treatment.
The overexpression of a G2/M transition and DNA damage gene signature by samples in
Branch A might have been driven by differences in the degree of tumor aneuploidy or by the
rate of proliferation. Neither sample group (Branch A and Branch B) showed consistent
differences with regard to DNA copy number aberrations (A. Angstadt et al, manuscript
submitted), and most sample genomes were cytogenetically chaotic [15], suggesting
groupings were not due to aneuploidy. We hence examined in vitro sensitivity to the mitotic
poison paclitaxel in six cell lines (three from each branch). Table 4 shows the half-maximal
inhibitory concentration for growth in three paclitaxel-sensitive human cell lines was <25
ng/ml (<30 nM). In contrast, only one of six canine osteosarcoma cell lines tested
(OSCA-71, which clustered to Branch A) showed paclitaxel sensitivity in this nM dose
range. Indeed, chemosensitivity was not predictive for outcome and it was independent of
the gene signature, suggesting the differential gene expression was not driven simply by
cellular proliferation rate.
We showed previously that dog breeds can influence tumor genotypes in lymphoma [25]
and osteosarcoma [16], as well as gene expression phenotypes hemangiosarcoma [18]. In
addition, Liao et al [26] showed that ~80% of Rottweilers carry a constitutional mutation in
c-MET, which might affect signaling and behavior in osteoblasts and osteosarcoma cells.
Thus, we predicted that osteosarcoma gene expression profiles might show a similar
association with breed in our cohort study, since the sample population included a
Rottweiler bias. The major branches observed by hierarchical clustering (of samples)
showed 10/13 Rottweilers included in the analysis segregated to Branch A and 3/13
segregated to Branch B (Supplementary Figure 2A). We therefore examined if these two
variables (Rottweiler, tumor with aggressive biological behavior and worse outcome) were
associated or independent.
The hierarchical clustering was based on the analysis of all 17,482 informative genes. Thus,
multiple independent factors could account for the segregation of samples into the two
branches. In other words, there were three factors that could show a dependent relationship
(A=C, B=C, A=B) or an independent relationship (A=C, B=C, A≠B). If the observed
contribution from “outcome” to the organization of the clusters were dependent on
Rottweilers having poor survival, then Rottweilers in general also should have poor survival.
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This hypothesis was tested and rejected in a previous multi-institutional retrospective study
[27]. Nonetheless, we evaluated overall survival time of Rottweilers vs. non-Rottweiler dogs
from both the 26-dogs with osteosarcoma in the profiled subset and in the full 79-dog
cohort. Our analysis similarly rejected the hypothesis that Rottweiler breed was the main
driver for survival, since no survival difference was detectable in survival between
Rottweilers (9/13 with survival annotation) and non-Rottweilers (12/13 with osteosarcoma
and survival annotation) included in the array (Supplementary Figures 2B) or between
Rottweilers (22/37 with survival annotation) and non-Rottweilers (27/42 with survival
annotation) in our larger sample set (Supplementary Figure 2C). This suggests that being a
Rottweiler (heritable background) and having a tumor with aggressive biological behavior
(worse outcome) were not associated and each may have contributed independently to the
hierarchical clustering. In other words, our data are most compatible with the model A=C,
B=C, A≠B, and that even though tumors from Rottweilers might share some molecular
features, they don t necessarily share biological behavior.
We next examined the correlation between the two molecular subgroups and biological
behavior or outcomes in the annotated canine and human cohorts (Figures 4 and 5). O
Donoghue et al selected dogs based on time to metastasis after standard of care. The groups
resulting from unsupervised analysis of the data from this cohort contained a mixture of
dogs that had early metastasis and delayed metastasis. The median time to metastasis in the
groups corresponding to Branch A (worse outcome) and Branch B (better outcome) was 100
and 360 days (3.26 and 12 months), respectively (Figure 4C). This difference represents a
strong trend, but the sample size was not large enough to reach statistical significance. Mintz
et al [8] originally analyzed samples from the New York cohort supervised according to
chemosensitivity as defined by percent necrosis using the Huvos grading system. Their
supervised gene expression analysis allowed them to identify a 104-gene chemoresponsive
signature from these samples. As predicted by the data in Table 4, the chemosensitivity
signature did not generally overlap our biological signature, likely reflecting the variety of
factors that influence tumor necrosis in vivo and the inconsistent predictive value for percent
necrosis [8, 9]. Cleton-Jansen et al [9] carried out supervised expression analysis according
to chemosensitivity and clinical response (5-year survival). Their data did not show
differences in gene expression profiles based on either parameter. When we applied our
gene signature to this cohort, the distinct pattern of two inversely related gene clusters seen
in our canine cohort was evident: the osteosarcoma samples clustered into two subgroups
(Figure 5D), with the subgroup that was equivalent to Branch B including fewer patients
with metastatic disease (5 of 12 vs. 8 of 13) and retaining a pattern that was more similar to
that seen in normal cells in this data set (data not shown). Similarly, supervised expression
analysis was performed with the Japanese osteosarcoma cohort according to the occurrence
of metastatic disease within four years in 19 of 27 samples [11]. We included all 27 samples
in our unsupervised analysis (Figure 5E). The samples once again segregated into distinct
subgroups of osteosarcoma with no predictive value for initial chemosensitivity, but 6 of 14
patients in the predicted “worse outcome” (Branch A) group showed metastasis by four
years, compared to 2 of 15 in the predicted “better outcome” (Branch B) group. Figure 5F
shows data from 34 samples reported by Paoloni [13] with known outcome. After
unsupervised expression analysis of these samples with our signature, analysis of survival
trends between the two resulting groups (Figure 7) showed that early therapy failures were
more common among patients in Branch A (8/18 patients dead and one censored, or 55%
survival at 1,200 days) as compared to patients in Branch B (3/16 patients dead and two
censored, or 80% survival at 1,200 days). The relatively small sample size would require an
unrealistically large difference in survival to reach significance using the log-rank test.
Nevertheless, the data from this cohort are consistent with the observations for the cohorts in
Figure 5D and Figure 5E, suggesting that grouping human osteosarcomas according to this
gene expression signature can predict tumor behavior as it does in canine osteosarcomas.
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The mechanisms that control osteosarcoma etiology and progression remain incompletely
understood. This disease is predominantly seen in children and adolescents, and occurs
naturally with greater frequency in dogs. Considering the similar clinical presentation, we
postulated evolutionarily conserved molecular traits for this disease would be present in both
species. Thus, the narrower genetic diversity of dogs would enhance our ability to define
biologically and clinically significant traits.
Gene expression profiling allowed us to define two distinct molecular subgroups of canine
osteosarcoma. Recent data showing that cells derived from Branch A tumors show more
facile and aggressive growth in laboratory animals, including spontaneous metastasis after
orthotopic invasion further support this pathological stratification [28]. Furthermore, the
clustering defined by this signature was seen repeatedly in three and five unrelated data sets
from dogs and humans, respectively, although the human subsets showed more extensive
branching into smaller subsets, suggesting osteosarcoma may have more complex behavior
in humans. The apparent difference in tumor heterogeneity between humans and dogs could
be explained by the reduced complexity of the canine genetic structure, where unlike
humans, risk haplotypes are more firmly embedded in the defined populations we call
breeds [29]. Thus, the contribution of any allele to modulate the biological behavior of
osteosarcoma is smaller in humans than it is in dogs, resulting in greater complexity of
inherited risk factors that in turn manifest as increased inter-tumor and intra-tumor
heterogeneity. Nonetheless, when we consider known differences between canine and
human osteosarcoma, such as the age of disease onset and the palliative vs. curative
treatment applied to these species, respectively, the similarities observed in their molecular
signatures and associated biological behaviors are remarkable. Clearly, this signature was
revealed in our analyses by eliminating stromal components through the use of tumor cells
grown in culture, as well as by using canine samples, which reduced the intrinsic variation
from heterogeneous genetic backgrounds of humans, in an unbiased (unsupervised) manner.
Despite repeated attempts and the application of numerous algorithms, previous
unsupervised analyses failed to segregate samples from intact tumor tissues (i.e., including
tumor cells and stroma) from dogs or humans into meaningful groups. Thus, even though
the gene expression signature was present in these intact tumor samples from both species, it
was masked by stromal signatures can modulate the balance of expression for some of the
genes [30]. The significance of this restricted gene list is further underscored by its capacity
to segregate independent cohorts into distinct branches, where each branch likely represents
a molecular subtype with unique and potentially predictable biological behavior.
At this time, incomplete data annotation in the cohorts precludes definitive assessment of the
prognostic value for these signatures, but the trends suggest that this signature or
components thereof may be of prognostic significance both in humans and dogs,
underscoring the similarities of this naturally occurring disease in both species. It is
especially intriguing that the cell cycle component of this profile shows exquisite overlap
with a predictive signature called CINSARC (Complexity Index in SARComa) recently
defined for soft tissue sarcomas. Chibon et al showed that CINSARC predicted survival
more robustly than the FNCLCC histologic grading system across multiple soft tissue
sarcomas, gastrointestinal stromal tumors, breast carcinomas, and lymphomas [12]. The
CINSARC signature consists of 67 cell cycle genes, of which 40 are present as orthologs in
Cluster 1 from our study, and an additional seven are members of families with retained
homologs (e.g., three CENP family genes, CHEK1, PAK3, SGOL2, and SMC2). Most
genes in this signature are coordinately regulated during the G2/M transition and/or as part
of the DNA damage checkpoint. Our Gene Cluster 1 and CINSARC have many elements in
common with prognostic signatures that also have been identified in urothelial cancer [31]
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and melanomas with B-Raf mutations [32]. Tumors with hyperactive DNA damage
responses also possess greater chemoresistance [33], possibly reflecting enrichment of
cancer stem cells [34]. This is not only a theoretical association derived from work in vitro,
in silico, or in transgenic models; empirical data confirmed that induction of DNA damage
responsive genes after radiation therapy, was associated with significantly worse survival
outcomes in two independent cohorts of breast cancer patients [35].
The reason why tumors with elevated cell cycle and DNA damage signatures show more
aggressive progression than tumors with elevated expression of genes that modulate
microenvironment interactions such as angiogenesis, cell migration, etc. is unclear.
However, two non-mutually exclusive explanations are consistent with this observation. The
first possibility is that the most aggressive tumors are likely to overcome constraints
imposed by the tissue niche, while less aggressive tumors retain characteristics of their
tissue of origin and are more dependent on the niche. In essence, the mutational profile may
reflect the degree of tumor differentiation and select largely for cells that can survive and
divide rapidly without much regard for their surrounding microenvironment. These cells
might therefore show greater metastatic efficiency, simply measured by their ability to
survive outside the original tumor [36], and in this case, metastatic efficiency would be
driven by cell-intrinsic factors and not by alterations in the microenvironment such as tissue
hypoxia, pH, or the extracellular matrix. The second possibility is that the signature
associated with elevated G2/M transition and DNA damage genes reflects enrichment of
tumor-initiating cells, which have been documented in osteosarcoma [37]. Either of these
possibilities, or perhaps both acting in concert, might be responsible for the differential
behavior and consequently the observed molecular pathological stratification of
osteosarcoma patients into two groups with distinct outcome.
Additional work will be necessary to define the molecular mechanisms that underlie this
gene expression signature and to further explore the role of genetic background in tumor
susceptibility in both dogs and humans.
5. Conclusion
We show here that naturally occurring canine and human appendicular osteosarcoma share
molecularly distinct subtypes associated with biological behavior; thus, studies in dogs that
can be conducted efficiently and in a relatively short timeline may provide prognostically
valuable information. The signatures that define these subtypes were revealed using
strategies that reduce inter-sample heterogeneity, including utilization of naturally occurring
canine tumors along with innovative comparative and gene vector based bioinformatic
analyses. We propose that both of these approaches are broadly applicable to the study of
tumor complexity, genetic heterogeneity, and evolutionary relationships in cancer.
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• Gene expression profiling reveals prognostic subgroups in canine osteosarcoma
• This molecular signature is highly preserved in human osteosarcoma patients
• It recapitulates a soft tissue sarcoma profile with potential bone-specific factors
• The narrower genetic diversity of dogs simplifies pathological stratification
• This unmasks biologically and clinically relevant molecular osteosarcoma
subtypes
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Figure 1. Unsupervised hierarchical clustering defines two osteosarcoma subtypes characterized
by two reciprocal gene clusters
(A) Unsupervised Clustering using expression data corresponding to 17,482 Entrez Gene
IDs reveals two major branches in 26 dogs with osteosarcoma and one dogs with non-
malignant osteomyelitis (OSCA 41), identified respectively as Branch A and Branch B in
the toe bar. (B) Heat map showing 282 differentially expressed transcripts (p ≤0.0068, mean
average fold-change >3) divided into two reciprocally expressed gene clusters (Gene Cluster
1 and Gene Cluster 2) between dogs in Branch A and Branch B. Heat map colors represent
median-centered fold change expression following log2 transformation (a quantitative
representation of the colors is provided in the scale at the bottom). Up-regulated genes are
shown in red and down-regulated genes are shown in green.
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Figure 2. Correlation between qRT-PCR and array data in a subset of nine osteosarcoma cell
lines
Pearson correlation for expression of (A) CCNB2 (R2=0.86), (B) CHEK2 (R2=0.72); and
(C) CADH6 (R2=0.83) genes. Each graph shows expression fold differences following
normalization to GAPDH and relative to OSCA 41 (non-malignant osteomyelitis sample)
for both the qRT-PCR on the x-axis and the microarray results on the y-axis. Data are shown
as log10 for both quantification methods.
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Figure 3. Immunohistochemistry for Cyclin B2 in primary tumors
Primary tumor samples corresponding to the dogs for OSCA 41 (panel A, osteomyelitis
showing low CCNB2 gene expression), OSCA 25 (panel B, Branch A-high CCNB2 gene
expression), OSCA 32 (panel C, Branch B- intermediate CCNB2 gene expression), and
OSCA 57 (panel D, Branch B-low CCNB2 gene expression) were stained using H&E or
antibodies against Vimentin (control) or Cyclin B2. (E) mRNA levels (expressed as array
units) for Vimentin and CCNB2 in the lines from the same tumor samples.
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Figure 4. Gene expression signature with inverse gene clusters is present in three independent
cohorts of dogs with osteosarcoma
(A) Heat map of canine samples from Figure 1B with six additional samples derived from
whole tumors. Data are shown relative to expression in cell lines. Yellow and blue tags
identify specific gene vectors in the signature for tracking in panels B and C. Color intensity
shows inter-sample variation. (B) Heat map of 15 canine samples from GEO GSE1608812
[13] using the gene list from Supplementary Table 3. The annotation for Affymetrix
Canine1.0 array platform is limited, allowing only 31 genes to be mapped by name. (C) Heat
map of 15 canine samples from GEO GSE24251 [14] using the gene list from
Supplementary Table 3. The full complement of genes in Supplementary Table 3 was
mapped to this cohort. Inverse gene expression patterns are present and gene vectors cluster
together. Toe bars indicate the corresponding Branches (A and B), and clusters with
predominance (<90%) of genes from Gene Clusters 1 and 2 are indicated for each sample
cohort.
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Figure 5. Gene expression signature with inverse gene clusters is present in five independent and
geographically diverse cohorts of humans with osteosarcoma
(A) The heat map of canine samples from Figure 4A is repeated for reference. Yellow and
blue tags identify specific gene vectors in the signature for tracking in panels B-E. Color
intensity shows inter-sample variation. (B) Unsupervised clustering of 31 samples from
Mintz [8], originating from New York, USA, profiled on the Affymetrix HG_U95Av2
platform using log transformed expression data. (C) Unsupervised clustering of two normal
bone tissue samples (indicated by purple box in bottom toe bar) and a cohort of 15 primary
osteosarcoma samples (indicated by the light blue box) originating from Minnesota, USA,
and three human osteosarcoma cell lines, two in duplicate (indicated by the red box) profiled
on an Illumina bead array using log-transformed expression data. (D) Unsupervised
clustering of samples from Cleton-Jansen [9], including 25 patients with osteosarcoma
originating from the Netherlands profiled on the Affymetrix Human 133A platform using
log transformed expression data. (E) Unsupervised clustering of samples from Kobayashi
[11], including 27 Japanese patients with osteosarcoma profiled on the Affymetrix Human
U133 Plus 2.0 platform using log transformed expression data. F) Unsupervised clustering
of human osteosarcoma samples from Paoloni [13] including 34 pre-treatment primary
tumors profiled on the Affymetrix HG 133A platform using log transformed data. Toe bars
indicate the corresponding Branches (A and B), and clusters with predominance (<90%) of
genes from Gene Clusters 1 and 2 are indicated for each sample cohort.
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Figure 6. Unsupervised hierarchical clustering defines two clinically significant groups in canine
osteosarcoma
The hierarchical cluster from Figure 1A is repeated for reference, along with Kaplan-Meier
survival (KM) and log rank analysis of 21 dogs in the cohort with known survival outcomes.
The toe bar defines groups for the KM analysis. Dogs from which OSCA 1, OSCA 8, OSCA
11, OSCA 56, and OSCA 73 samples were derived were lost to follow-up (no survival data
was available) and the dog from which OSCA 41 was derived had osteomyelitis. The
median survival time for dogs in Branch A was ∼2.8 months, and the median survival time
for dogs in Branch B was ∼14.0 months.
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Figure 7. Kaplan-Meier survival analysis using groups defined by the clustering of orthologous
canine genes in human samples
Annotated survival data are from Paoloni [13]. (A) Overall survival for all patients at >4,900
days; censored patients that were alive at last follow-up are shown as tick marks above each
line. The red line represents samples from Branch A and the gray line represents samples
from Branch B. (B) Tabulation of early failures (deaths by 1,200 days, or ∼3 years) in 200-
day intervals from patients in Branch A (red) and Branch B (gray), respectively.
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Table 1
Metadata data from complete cohort of 79 dogs (78 recruited with primary appendicular osteosarcoma and 1
with osteomyelitis) and restricted group of 27 dogs analyzed by gene expression profiling
Variable
Recruited Cohort (N =79) GEP Analysis Group (N= 27)
Number (%3) Number (%)
Male 38 (48%) 15 (56%)
Female 39 (49%) 11 (41%)
Unknown 2 (3%) 1 (3%)
Median Age at Diagnosis (Years) 8.03 6.14
Range of Age (Years) 1–13.91 2–11.2
Golden Retrievers 15 (19%) 7 (26%)
Other 27 (34%) 7 (30%)
Osteoblastic 45 (57%) 18 (66%)
Fibroblastic 16 (20%) 4 (15%)
Chondroblastic 9 (11%) 3 (11%)
Mixed 4 (5%) 1 (4%)
Osteomyelitis 1 (1%) 1 (4%)
Unknown 4 (5%) 0 (0%)
Median Survival (months)
All Dogs 4.06 4.96
Standard of care1 10.36 11.01
Limb amputation 3.85 1.18
Palliative care2 1.15 0.18
1
Removal of primary tumor by amputation or limb-sparing surgery with adjuvant chemotherapy
2
Pain medication, radiation therapy, or alternative therapies (herbal, homeopathic, etc.)
3
Percents may not add to 100 due to rounding
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Table 2
Ingenuity pathway analysis of 282 transcripts showing significant association with functional cancer pathways
IPA Function Annotation B-H p-value
Cell division process 3.21E-21
Cell division process of chromosomes 5.78E-18
Cell stage 6.95E-18
Mitosis 7.49E-16
Cell stage of cervical cancer cell lines 7.88E-14
Cell cycle progression 8.98E-14
Segregation of chromosomes 4.93E-13
Neoplasia 6.50E-11
Tumorigenesis 6.50E-11
Cell division process of eukaryotic cells 1.44E-10
Cell division process of tumor cell lines 1.52E-10
Ploidy 3.55E-10
Mitosis of tumor cell lines 5.43E-10
Cancer 6.43E-10
Delay in cell stage 1.33E-09
Colon cancer 1.33E-09
Alignment of chromosomes 1.36E-09
Cell division process of cell lines 6.47E-09
Colorectal cancer 7.46E-09





Initiation of replication of DNA 6.95E-07
Formation of mitotic spindle 1.03E-06
Segregation of sister chromatids 1.32E-06
Proliferation of cells 1.41E-05
Checkpoint control 2.42E-05
Cytokinesis 6.51E-05
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Table 3
Demographic Characteristics of Dogs and Correlation with Clustering
Variable No. of Cases P - value




 Male 10 5
 Female 6 5
 Unknown 0 1
Age at Diagnosis (Months)a
0.53c
0.69d
 ≤ 7 9 4
 > 7 7 6
 Unknown 0 1
Histology
0.53
 Osteoblastic 12 6
 Chondroblastic 1 2
 Fibroblastic 2 2
 Mixed 1 0
 Osteomyelitis 0 1
Treatment Regimen
0.55
 Standard of care 9 6
 Limb amputation 2 1
 Palliative care 3 0
 Unknown 2 3
Survival (Months)b
0.02 ≤ median 10 1




 Rottweiler 10 3
 Golden Retriever 3 4
 Other 3 4
a
Median age at diagnosis for all dogs = 6.14 years
b








Rottweiler vs. Golden Retriever vs. Other
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Table 4
Half-maximal inhibitory concentration of paclitaxel for canine osteosarcoma cell lines from Branch A and
Branch B in vitro
Cell Line Paclitaxel IC50 (ng/ml)
U937 (human leukemia) 1
HL-60 (human leukemia) 25
K562 (human leukemia) 20
OSCA-19 (Branch A) 10,000
OSCA-25 (Branch A) NR*
OSCA-71 (Branch A) 15
OSCA-17 (Branch B) 10,000
OSCA-23 (Branch B) NR
OSCA-32 (Branch B) 30,000
*
NR = not reached (>50,000)
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